DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. It offers Dario Engage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications, and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy and distributors; and through e-stores. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone972-4770-4055
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.39 million
Profitability
Miscellaneous
Employees69
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable
DarioHealth (NASDAQ:DRIO) Frequently Asked Questions
What is DarioHealth's stock symbol?
DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."
How were DarioHealth's earnings last quarter?
DarioHealth Corp (NASDAQ:DRIO) released its quarterly earnings results on Monday, May, 13th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.02. The business earned $2.24 million during the quarter. DarioHealth had a negative net margin of 257.11% and a negative return on equity of 296.31%. View DarioHealth's Earnings History.
When is DarioHealth's next earnings date?
What price target have analysts set for DRIO?
1 brokers have issued 12-month price objectives for DarioHealth's shares. Their predictions range from $1.50 to $1.50. On average, they anticipate DarioHealth's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 206.1% from the stock's current price. View Analyst Price Targets for DarioHealth.
What is the consensus analysts' recommendation for DarioHealth?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DarioHealth.
Has DarioHealth been receiving favorable news coverage?
Media headlines about DRIO stock have been trending somewhat negative on Thursday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. DarioHealth earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for DarioHealth.
Who are some of DarioHealth's key competitors?
Some companies that are related to DarioHealth include Nuvectra (NVTR), Invo Bioscience (IVOB), Spectral Medical (EDTXF), Pro-Dex (PDEX), AIT Therapeutics (AITB), Arch Therapeutics (ARTH), Titan Medical (TMDI), Nephros (NEPH), RA Medical Systems (RMED), Neovasc (NVCN), PAVmed (PAVM), Avinger (AVGR), SANUWAVE Health (SNWV), Interpace Diagnostics Group (IDXG) and Lianluo Smart (LLIT).
What other stocks do shareholders of DarioHealth own?
Who are DarioHealth's key executives?
DarioHealth's management team includes the folowing people:
- Mr. Erez Raphael, CEO & Director (Age 46)
- Mr. Olivier R. Jarry, Pres & Chief Commercial Officer (Age 58)
- Mr. Zvi Ben David, CFO, Treasurer & Sec. (Age 58)
- Mr. Dror Bacher, Chief Operating Officer (Age 44)
- Ms. Joao Mendes-Roter, VP of Marketing
Who are DarioHealth's major shareholders?
DarioHealth's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perkins Capital Management Inc. (0.66%). Company insiders that own DarioHealth stock include Allen Kamer, Erez Raphael, Hila Karah, Yoav Shaked and Zvi Ben-David. View Institutional Ownership Trends for DarioHealth.
Which institutional investors are buying DarioHealth stock?
DRIO stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. Company insiders that have bought DarioHealth stock in the last two years include Allen Kamer, Erez Raphael, Hila Karah, Yoav Shaked and Zvi Ben-David. View Insider Buying and Selling for DarioHealth.
How do I buy shares of DarioHealth?
Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DarioHealth's stock price today?
One share of DRIO stock can currently be purchased for approximately $0.49.
How big of a company is DarioHealth?
What is DarioHealth's official website?
How can I contact DarioHealth?
DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at 972-4770-4055 or via email at [email protected]
MarketBeat Community Rating for DarioHealth (NASDAQ DRIO)
MarketBeat's community ratings are surveys of what our community members think about DarioHealth and other stocks. Vote "Outperform" if you believe DRIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
